AstraZeneca and Daiichi Sankyo’s star drug Enhertu has … first-line application is under FDA priority review, with a decision … just been accepted by the FDA, with a target action date …

… oncology stars. Last year, the Daiichi Sankyo-partnered drug generated $1.98 … . YOU MAY ALSO LIKE: The FDA Just Granted Its Speediest Review …

… -drug-conjugates-market--clinical-trials-fda-approved-lung-cancer-adc The … 3 candidates, including Merck and Daiichi Sankyo's Ifinatamab Deruxtecan (anti … players. Pharmaceutical giants such as Daiichi Sankyo, Pfizer, and Roche are developing …

… therapy based on an FDA-approved companion diagnostic … trial in collaboration with Daiichi Sankyo evaluating raludotatug deruxtecan ( … Food and Drug Administration (FDA) for the treatment … by Daiichi Sankyo and is being jointly developed by Daiichi Sankyo and …

… FLAURA2 supported the 2024 FDA approval of osimertinib … supported the February 2024 FDA approval of osimertinib … PUMA, Astellas Pharmaceuticals, and Daiichi Sankyo. He also is the co … information-approved-drugs/fda-approves-osimertinib-chemotherapy-egfr …

… from NIAGARA supported the FDA’s approval of neoadjuvant … Pfizer, Seagen, Janssen, and Daiichi Sankyo. References 1. van der Heijden … /NEJMoa2408154 4. FDA approves durvalumab for muscle … information-approved-drugs/fda-approves-durvalumab-muscle-invasive …

… of ALEX led to the FDA approval of alectinib in April … -financial support from AbbVie Inc., Daiichi Sankyo, and MIRXES; personal fees including … . doi:10.1056/NEJMoa1704795 FDA approves Genentech's Alecensa …

… Data from NIAGARA supported the FDA’s approval of neoadjuvant durvalumab … , Astellas, Pfizer, Seagen, Janssen, and Daiichi Sankyo. REFERENCES: 1. van der Heijden …

… and racked up dozens of FDA-approved indications, the drug is … . Despite boasting more than 40 FDA approvals, Keytruda hasn’t been … carries three FDA approvals. Merck is additionally testing a Daiichi Sankyo-partnered antibody …

… Bristol Myers Squibb announced FDA has accepted the supplemental … follicular lymphoma to the FDA. The company anticipates a … decision from the FDA by the second half … Pharma, Seagen, Takeda, Novartis, Daiichi Sankyo, Genmab, AbbVie, Genentech (a Member …